Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...

4′-Fluorouridine works against RNA-dependent RNA polymerase, an enzyme that helps viruses assemble RNA. The compound has a ...

Computational biologists from the National University of Singapore (NUS) have uncovered how RNA splicing—a crucial process ...

After about five years working behind the scenes, Arrakis Therapeutics is unveiling that its lead program will aim to treat ...

Dominique Verhelle is co-founder and CEO of the Brighton-based company NextRNA Therapeutics, which uses long non-coding RNA ...

This research report explores the global RNA sequencing market, providing an analysis of its trends and projections through 2029. It breaks down the market by product, technology, application, end ...

ArrakisTx was formed to create RNA-intercepting drugs to fight cancer. Despite some promising data, CEO @michael_gilman says it will shift targets.

With a novel approach, EMBL scientists discovered important interactions between molecular machines, potentially offering new ...

Gut microbiota from primates with larger brains promotes glucose production and energy allocation for brain function, ...

Sum 41 have had an unfortunate non-starter to their final Australian tour, being forced to cancel the first night at Brisbane ...